Technology Report:

Radiation Therapy

334 6201840297001

Technology Report: Patient-centered Care in Radiation Therapy

Radiation therapy has become increasingly effective and safe as vendors continue to innovate technologies that benefit the patient. At ASTRO 2018, this patient-centric approach was exemplified and demonstrated not only in ways that match treatments to patients, but in how technologies can adjust to patient movement and anatomical changes, and to increase the precision of treatments. ITN Contributing Editor Greg Freiherr showcases several new technologies that are helping to advance this field.

For additional patient-centered care coverage, see:

Conversations with Greg Freiherr: The Accuray Philosophy

ASTRO Puts Patients First

Related Content

RaySearch Laboratories AB announced an extension of its relationship with Centre hospitalier universitaire vaudois (CHUV) in Lausanne, Switzerland, which will include orders for RayStation RayCare and RayIntelligence. 
News | June 28, 2021
June 28, 2021 — RaySearch Laboratories AB announced an extension of its relationship with...
The two-year project focused on reducing the use of extended-fraction radiation therapy to treat pain from incurable cancer that had spread to patients’ bones. Once a standard practice, the American Society for Radiation Oncology (ASTRO) has recommended against the routine use of extended-fraction radiation to relieve pain from bone metastases, especially more than 10 treatments.

Multiple cancer metastasis to the pelvic bone and femur bones. Getty Images

News | June 24, 2021
June 24, 2021 — An effort by the Michigan Radiation Oncology Quality Consortium ...
 Mevion Medical Systems announced that the first proton center in the Mountain West, the Senator Orrin G. Hatch Center for Proton Therapy, has opened at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) and began treating patients on May 11 with the MEVION S250i Proton Therapy System.

The teams from HCI, U of U and Mevion gather to celebrate the center’s grand opening. Group from left to right: Bill Salter, Ph.D., Senior Director of Radiation Oncology, HCI and Professor and Chief of the Division of Medical Physics, U of U -- Robyn Walker, Sr. Director, Customer Success and Service Operations, Mevion -- James Cooley, Ph.D., Director of Advanced Development, Mevion -- Dennis Shrieve, M.D., Ph.D., Chair in Cancer Research, HCI and Chair of Department of Radiation Oncology, U of U -- Tina Yu, Ph.D., CEO, Mevion -- Michael Good, M.D., Interim President, U of U and Sr. VP for Health Sciences, U of U Health -- Ying Hitchcock, M.D., Professor and Medical Director, Department of Radiation Oncology, U of U. (Photo: Business Wire)

News | June 24, 2021
June 24, 2021 — Mevion Medical Systems announced that the first proton center in the Mountain West, the Senator Orrin
Master Supply Agreement encompasses clinical development and commercial supply for Clarity’s Cu-67-based candidates to treat neuroblastoma, breast and prostate cancers, among others
News | June 22, 2021
June 22, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercia
Elekta Harmony linear accelerator cleared by U.S. Food and Drug Administration
News | June 18, 2021
June 18, 2021 — Elekta announced that its Elekta Harmony...
The impact of deploying artificial intelligence (AI) for radiation cancer therapy in a real-world clinical setting has been tested by Princess Margaret researchers in a unique study involving physicians and their patients.

Getty Images

News | June 15, 2021
June 15, 2021 — The impact of deploying ...
Accuray Incorporated announced the company has received CE Mark certification for its ClearRT helical fan-beam kVCT imaging capability.
News | June 11, 2021
June 11, 2021 — Accuray Incorporated announced the company has received CE Mark certification for its...
Blog | June 07, 2021
 
Prof. Jayant Vaidya, lead author of the study, University College London surgery and interventional science, performs a TARGI-IORT procedure. A small ball-shaped device placed inside the breast, directly where the cancer had been. The single-dose treatment lasts for around 20-30 minutes and replaces the need for extra hospital visits in eight out of ten cases.

Prof. Jayant Vaidya, lead author of the study, University College London surgery and interventional science, performs a TARGI-IORT procedure. A small ball-shaped device placed inside the breast, directly where the cancer had been. The single-dose treatment lasts for around 20-30 minutes and replaces the need for extra hospital visits in eight out of ten cases.

News | June 02, 2021
June 2, 2021 — A breast cancer therapy that requires just one shot of radiotherapy is as effective as traditional rad